

1 **The impact of diabetes mellitus and HBV infection on major**
2 **adverse cardiovascular events related to statin use for Chinese**
3 **population with cardiovascular disease**

4 **Running title:** Effect of DM or HBV infection on MACEs.

5

6 Qian Wu^a, MM; Xiaoxuan He^a, MM; Xiaoning Tong^a, MM; Ying Li^b,MM; Xiaoqin
7 Wang^a, MD

8 ^aDepartment of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong
9 University, Xi'an, 710061, Shaanxi Province, China.

10 ^bDepartment of Clinical Laboratory, Shaanxi Kang Fu Hospital, Xi'an,710065,
11 Shaanxi Province, China.

12

13 Qian Wu and Xiaoxuan He contributed equally to this work.

14

15 **Correspondence to:** Dr. Xiaoqin Wang, M.D. Department of Clinical Laboratory,
16 The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road,
17 Xi'an 710061, Shaanxi Province, China. E-mail: wq710641296@xjtufh.edu.cn.

18

19 **Clinical Perspective**

20 **What Is New?**

21 • This study investigates the association between statin therapy and major adverse
22 cardiovascular events (MACEs) in Chinese patients with cardiovascular disease who
23 have concurrent hepatitis B virus infection or diabetes mellitus.

24 • The findings suggest potential cardiovascular benefits of statin therapy in this

25 specific patient population.

26 • The study explores the relationship between statin use and changes in hepatic
27 function, atherosclerotic markers, and inflammatory parameters.

28 **What Are the Clinical Implications?**

29 • The results provide evidence supporting statin use in cardiovascular disease patients
30 with hepatitis B virus infection or diabetes mellitus.

31 • Glycemic control appears to be an important factor in optimizing cardiovascular
32 outcomes in these patients.

33 • Regular monitoring of hepatic and inflammatory markers may be valuable in
34 assessing treatment response.

35 **BACKGROUND:** The association between hepatitis B virus (HBV) infection, diabetes mellitus
36 (DM) and cardiovascular disease (CVD) remains uncertain. This study was aimed to investigate
37 the impact of HBV infection and DM on 13 major adverse cardiovascular events (MACEs) among
38 CVD patients with or without statin use.

39 **METHODS AND RESULTS:** In total, 45,013 individuals participated in the baseline survey
40 between June 2020 and August 2023. The patients were categorized into two groups according to
41 their surface antigen status. Finally, a sample size of 496 participants was included in the study:
42 patients with coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271).The
43 implementation of statins has demonstrated the potential to reduce the incidence of coronary heart
44 disease (CHD) and angina pectoris (AP) in individuals with CVD who are also affected by HBV
45 infection. The analysis of stratification, taking into account the presence of DM, has demonstrated
46 a significant increased vulnerability to myocardial infarction (MI), acute myocardial infarction
47 (AMI), and heart failure (HF) among individuals with HBV infection combined with CVD. DM
48 and hemoglobin A1c (HBA1c) level of ≥ 6 are identified as risk factors for the development of
49 CHD, MI, AP, and hypertension. Our study also suggests that statin therapy led to a
50 dose-dependent decrease in liver fibrosis, as well as improvement of the atherogenicity index and
51 systemic inflammatory response in patients with CVD.

52 **CONCLUSION:** Our study indicates that CVD patients who also have HBV infection or DM
53 may experience a reduction in MACEs when treated with statins. Furthermore, our research
54 indicates that focusing on long-term glycemic control is essential in this patient population in
55 order to enhance cardiovascular outcomes. The observed improvements in hepatic function,
56 atherosclerotic burden, and systemic inflammation associated with statin therapy may contribute
57 to the favorable cardiovascular outcomes among individuals with CVD.

58 **Key Words:** HBV ■ diabetes mellitus ■ CHD ■ cardiovascular disease ■ statins use

59 Coronary heart disease (CHD) is the primary cause of mortality in humans,
60 accounting for approximately 9 million deaths annually worldwide ¹. CHD
61 encompasses cardiovascular conditions resulting from the narrowing or obstruction of
62 the coronary arteries due to atherosclerosis, as well as myocardial ischemia, hypoxia,
63 or necrosis caused by functional alterations in these arteries ². Presently, there exists a
64 prevailing belief within the academic community that the presence of obesity,
65 smoking, and alcohol consumption plays a substantial role in the advancement of
66 CHD ^{3, 4}. Furthermore, it is worth emphasizing that hypertension, hyperlipidemia,
67 hypercholesterolemia, and diabetes mellitus (DM) also contribute to the development
68 of CHD ⁵⁻⁸. Notably, DM represents a significant risk factor, as the elevated blood
69 glucose levels experienced by individuals with this condition often induce oxidative
70 stress and inflammatory harm, ultimately resulting in atherosclerosis, coronary artery
71 dysfunction, myocardial infarction, and cellular impairment, thereby fostering the
72 progression of CHD ⁹. DM is additionally linked to an unfavorable long-term
73 prognosis in individuals diagnosed with CHD. In comparison to patients without DM,
74 those with DM complicated by CHD exhibit a higher mortality rate over a span of 10
75 years ¹⁰.

76 The global prevalence of Hepatitis B virus (HBV) infection is substantial, rendering it
77 a significant concern for public health. Prolonged HBV infection can result in chronic
78 hepatitis, cirrhosis, liver decompensation, and hepatocellular carcinoma ¹¹. Chronic
79 HBV infection is characterized by a state of inflammation, which has been observed

80 to elevate the likelihood of major adverse cardiovascular events (MACE) and
81 cerebrovascular disease in other conditions featuring chronic low-grade inflammation
82 ^{12, 13}. Several studies have examined the association between HBV infection and
83 cardiovascular disease (CVD); however, the findings have been inconclusive ¹⁴⁻¹⁷.
84 Certain studies have identified a positive correlation between HBV infection and
85 coronary artery disease ¹⁷, whereas others have indicated a negative correlation ¹⁴⁻¹⁶.
86 In individuals diagnosed with chronic viral hepatitis, it has been observed that those
87 with HCV infection exhibit a notably elevated susceptibility to composite arterial
88 events and all-cause mortality when compared to those with HBV infection ^{18, 19}.
89 Furthermore, investigations have indicated that there is no substantial association
90 between the prevalence of macrovascular complications, microvascular complications
91 of diabetes, diabetic ketosis, or diabetic ketoacidosis and the status of HBV infection
92 ²⁰. Hence, it is crucial to persist in the examination of the correlation between HBV
93 infection and MACE.

94 Statins have demonstrated efficacy in mitigating the occurrence of CVD and are
95 endorsed as the primary therapeutic approach for hypercholesterolemia in clinical
96 guidelines ^{21, 22}. The American College of Cardiology/American Heart Association
97 guidelines for managing blood cholesterol levels to minimize the risk of
98 atherosclerotic CVD (ASCVD) in adults have classified statins into low, moderate,
99 and high potency categories, based on comprehensive analysis of their lipid-lowering
100 effects across various clinical trials and direct comparisons. High-potency statins,
101 such as rosuvastatin at doses of 20 mg/d and 40 mg/d, and atorvastatin at doses of 40

102 mg/d and 80 mg/d, have exhibited a noteworthy decrease in low-density lipoprotein
103 cholesterol (LDL-C) levels surpassing 50% ²¹. Additionally, decreased cholesterol
104 levels by statin use may impact the advancement of hepatic fibrosis by ameliorating
105 portal hypertension and reducing the excessive accumulation of hepatic triglycerides
106 ²³⁻²⁵. Numerous clinical studies have demonstrated the efficacy of statin
107 administration in patients with NAFLD, leading to improvements in liver
108 ultrasonography and liver function tests ²⁶⁻²⁸. The independent association of statin
109 use with reductions in hepatic steatosis and fibrosis stage in NAFLD patients has also
110 been observed ^{26, 28}. The pathogenesis of hepatic fibrosis is characterized by a
111 multifaceted interaction between lipid metabolism and systemic chronic inflammatory
112 response in patients with CVD ^{29, 30}.

113 Hence, this study aimed to gather data on patients with both HBV and CVD, as well
114 as those with CVD alone, in order to examine the correlation between statin use and
115 HBV infection, DM, or hemoglobin A1c (HbA1c) levels among individuals with
116 CVD. Additionally, the study sought to assess the impact of HBV infection, DM,
117 HbA1c levels, or statin use on various cardiovascular outcomes in patients with CVD.
118 Currently, there is uncertainty regarding the impact of statins on hepatic fibrosis and
119 systemic inflammatory response, as well as their effects on CVD and lipid
120 metabolism. The identification of specific markers in this context remains ambiguous.
121 It is our assertion that the identification of suitable markers is crucial for the
122 monitoring of liver fibrosis and systemic inflammation in patients with CVD
123 undergoing statin therapy. Our research aimed to assess the impact of statin therapy

124 on hepatic fibrosis, systemic inflammation, and atherogenic indices in patients with
125 CVD.

126

127 **MATERIALS AND METHODS**

128 **Study design and participants**

129 A prospective cohort study was conducted to examine the prevalence, incidence, and
130 associated factors, such as HBV infection, in relation to CVD. The study was
131 approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong
132 University (No:XJTU1AF2024LSYY-054). In total, 45,013 individuals participated in
133 the baseline survey at the First Affiliated Hospital of Xi'an Jiaotong University (Xi'an,
134 China) between June 2020 and August 2023. Of these, 43,750 cases were excluded
135 due to HCV, HIV, syphilis infection, as well as incomplete basic data of test results
136 and medical records. A total of 268 patients presenting with hepatic hemangioma,
137 toxic diffuse goiter with hyperthyroidism, hypothyroidism, endometrial cancer, stage
138 5 hemodialysis status of chronic kidney disease, chronic renal insufficiency, skull
139 osteoma, and right lobe cyst of thyroid gland were excluded from the study.
140 Additionally, 499 cases with incomplete test data, including five quantitative variables
141 (disease load, blood cells, blood lipid, and other information), as well as incomplete
142 drug use information, were also excluded. Consequently, a final sample size of 496
143 participants was included in the study (refer to [Figure 1](#)). The patients were
144 categorized into two groups according to their surface antigen status: patients with
145 coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). In
146 addition, a sample size of 494 CVD participants was included, patients with statin use

147 (n = 415) and statin-free (n = 79), to investigate the effect of statin use on hepatic
148 fibrosis, atherosclerotic burden, and systemic inflammation.

149 **Clinical data collection and measurements**

150 The variables considered in this study encompassed patient demographics such as age
151 and gender, as well as medical factors including hypertension, smoking/alcohol
152 consumption, diabetes, disease status, biochemical indicators, blood cell indicators,
153 HBV five-item quantitative, HBV-DNA quantitative, statin use, antiviral therapy for
154 hepatitis B, and major adverse cardiovascular events. The ratios of platelet count to
155 lymphocyte count (PLR) and neutrophil count to lymphocyte count (NLR) are
156 computed to assess certain adverse cardiovascular events, such as recurrent angina
157 pectoris (AP), hospitalization for unstable angina pectoris (UAP), acute myocardial
158 infarction (AMI), severe arrhythmia, heart failure (HF), and death due to CHD. Major
159 adverse cardiovascular events include recurrent AP, UAP requiring hospitalization,
160 AMI, severe arrhythmia, HF, coronary-related death, etc. Secondary adverse
161 cardiovascular events include Killip classification II-IV or NYHA Classification
162 II-IV.

163 All specimens were tested within 2 hours following their collection. In cases where
164 immediate testing was not feasible, specimens were stored at a temperature of -20°C
165 for a duration not exceeding 2 days. The fluorescence quantitative PCR detection of
166 HBV-DNA load was conducted utilizing the 7500 fluorescence quantitative PCR
167 instrument and associated reagents (ABI, USA). Quantitative determination of
168 biochemical indicators was performed using the Roche AU5600 automatic

169 biochemical analyzer and its corresponding original reagents. The quantification of
170 the five components of serum hepatitis B was performed using the i2000sr instrument
171 manufactured by Abbott Laboratories, USA. The detection of blood cell indicators
172 was conducted using the routine automatic flow cytometer Mindray CAL8000. The
173 Roche E801 automatic immunoassay analyzer, along with original reagents, was
174 utilized for the quantitative determination of B-type natriuretic peptide (BNP) in the
175 anterior brain. HbA1c was assessed with high-performance liquid chromatography.
176 All aforementioned measurements were performed in accordance with the
177 manufacturer's instructions.

178 **Calculations of the albumin-bilirubin index (ALBI) score, fibrosis 4 index (FIB-4)**
179 **index, complete blood count derived inflammation index (CBCIIs) and**
180 **atherogenic indices.** Non-invasive and non-destructive testing markers, including
181 FIB-4, ALBI, and CBCIIs, such as platelet monocyte ratio (PMR),
182 neutrophil/lymphocyte ratio (NLR), SII, systemic inflammatory response index (SIRI),
183 and aggregate index of systemic inflammation, and atherogenic indices, such as
184 atherogenic index of plasma (AIP), atherogenic index (AI), Castelli risk index-I
185 (CRI-I), Castelli risk index-II (CRI-II), and triglyceride-rich lipoprotein cholesterol
186 (TRL-C) were used to evaluate the effects of statin use on hepatic fibrosis, systemic
187 inflammation, and arteriosclerotic degree in patients with CVD. The calculation
188 formulas of hepatic fibrosis indicators ALBI score, FIB-4 index were measured as
189 described previously ³¹. CBCIIs, including SIRI, SII, aggregate index of systemic
190 inflammation (AISI), SIRI/HDL-C, and SIRI×LDL-C, were calculated as described

191 previously^{32, 33}. Atherogenic indices, such as adjusted AIP, AIP, AI, CRI-I, CRI-II,
192 LCI, and TRL-C, were calculated as described previously³⁴⁻³⁷.

193 **Statistical analysis**

194 In the case of measurement data that conforms to a normal distribution, the mean \pm
195 standard deviation is employed for representation, and intergroup comparison is
196 carried out through the utilization of a t-test. Conversely, for measurement data that
197 does not adhere to a normal distribution, the median (quartile) [M (P₂₅ ~ P₇₅)] is
198 employed for representation, and intergroup comparison is conducted using the
199 Mann-Whitney U non-parametric test. Count data is represented using frequency and
200 percentage (%), and intergroup comparison is performed using either the chi-square
201 test or Fisher's exact probability method. The Breslow-Day test is employed for
202 conformance testing in hierarchical analysis, while the Mantel-Haenszel test is
203 utilized for hierarchical chi-square testing. To address potential confounding, logistic
204 regression models were used to estimate the odds ratio (OR) and 95% CI for MACE.
205 All statistical analyses were conducted using SPSS, version 22.0 (SPSS Inc, USA). A
206 2-tailed *P* value of less than 0.05 was considered to be statistically significant.

207 **RESULTS**

208 **Table 1** presents the demographic characteristics of the study participants. A total of
209 496 subjects were included in the analysis, comprising 225 individuals with pure
210 CVD and 271 individuals with CVD accompanied by HBV infection. Notably, the
211 CVD combined with HBV infection group exhibited a statistically significant increase
212 in the proportion of males and AMI when compared to the CVD alone group (both *P*

213 < 0.05). Furthermore, when comparing patients with CVD alone to those with CVD
214 combined with HBV, it was observed that the latter group exhibited elevated levels of
215 HBsAg, HbsAb, and HbcAb (all $P < 0.05$). Conversely, the CVD combined with
216 HBV group displayed lower levels of weight, medication dosage, TG, Lpa, PLR, and
217 PLT in comparison to the CVD alone group. Additionally, the proportions of diabetes
218 and pre-hospital medication were relatively lower in the CVD combined with HBV
219 group. Notably, the remaining indicators presented in **Table 1** did not demonstrate
220 statistical significance. The quantitative (**Supplementary table 1**) and qualitative
221 (**Supplementary table 2**) baseline characteristics and statistical comparisons of
222 individuals with CVD who were either using or not using statins were also
223 documented. It is evident that there are statistically significant differences in height,
224 weight, platelet count, alanine aminotransferase levels, and aspartate aminotransferase
225 levels among the three groups (all $P < 0.05$). The utilization of statins resulted in
226 lower TG ($P = 0.000$), LDL-C ($P = 0.000$), ApoB ($P = 0.000$), and non-HDL-C ($P =$
227 0.000) levels. Based on the findings presented in **Supplementary table 2**, it is evident
228 that there exist statistically significant disparities in gender, diabetes, and smoking
229 history across the three groups, with or without statin usage (all $P < 0.05$). It is worth
230 noting that long-term use of statins has been associated with an increased risk of DM
231 ³⁸. Consequently, clinicians may be avoiding prescribing statins to cardiovascular
232 patients with diabetes, leading to a higher proportion of non-statin use in this
233 population (65.8%). Conversely, no statistically significant variations were observed
234 in hypertension, alcohol history, and anti-HBV treatment among the three groups (all

235 $P > 0.05$).

236 **Relationship of Statin Use with HBV Infection and Quantification.** To examine
237 the relationship between statin use and HBV infection, we conducted a study
238 comparing HBV infection rates and quantitative parameters in patients both with and
239 without statin use. Our analysis revealed a significant association between statin use
240 and HBV infection rates ($\chi^2 = 76.835$, $P = 0.000$). Subsequent pairwise comparisons
241 demonstrated that the HBV infection rate in the group not using statins was 97.5%
242 (77/79), whereas the rate in the group using atorvastatin 20 mg was 40.4% (91/225),
243 indicating a protective effect with an OR of 0.018 (95% CI: 0.004 - 0.074). In the
244 rosuvastatin 10 mg group, the HBV infection rate was 53.7% (102/190), indicating a
245 potential protective effect with an OR of 0.030 (95% CI: 0.007 - 0.126). Furthermore,
246 the HBV infection rate was 40.4% (91/225) in the atorvastatin 20 mg group and 53.7%
247 (102/190) in the rosuvastatin 10 mg group, demonstrating a statistically significant
248 difference between the two groups ($P = 0.002$). This suggests that the HBV infection
249 rate in the rosuvastatin 10mg group was relatively higher, with an odds ratio of 1.94
250 (95% CI: 1.28 - 2.94) (**Table 2**). The HbsAg levels ranged from less than 0.05 to 250,
251 the Median Difference (0-1) was calculated to be 70 (95% CI: 26 to 125). Additionally,
252 the Median Difference (0-2) was found to be 63 (95% CI: 18 to 117). These findings
253 indicate that the quantification of HbsAg in individuals using statins is notably
254 reduced compared to those not using statins (**Table 3**). The analysis of the Median
255 Difference (1-2) yielded a value of 0 (95% CI: 0 to 0), suggesting a lack of
256 statistically significant disparity in the effectiveness of the two statins in reducing

257 HbsAg quantitation. However, the OR (atorvastatin/rosuvastatin) in Table 2 was
258 calculated as 1.94 (95% CI: 1.28 to 2.94), indicating a lower infection rate associated
259 with atorvastatin (**Table 3**). This apparent contradiction underscores the need for a
260 nuanced interpretation that considers both qualitative and quantitative aspects of the
261 investigation. Furthermore, when compared to the group not using statins, the
262 quantification of HBV-DNA and HBcAb was significantly lower in the statins use
263 group. Conversely, the quantification of HBsAb, HBeAg, and HBeAb was
264 significantly higher in the statins use group (**Table 3**). In addition, **Table 4**
265 demonstrates a significant dose-effect relationship between statin dosage and HbsAg
266 quantification ($P = 0.000$), indicating that higher doses result in lower HbsAg levels,
267 with the exception of a slight rebound observed at the highest dose of rosuvastatin 20
268 mg. Nevertheless, the limited sample size at this dosage level necessitates further
269 validation of these findings.

270 **The impact of HBV infection, stratified by statins use, on multiple clinical**
271 **outcomes among CVD patients.** In our study, atorvastatin and rosuvastatin emerge
272 as the prevailing lipid-lowering medications, with atorvastatin 20 mg and rosuvastatin
273 10 mg serving as the primary drug dosage combinations. This particular combination
274 is employed as a stratification factor to examine the impact of HBV infection on 13
275 clinical outcomes among individuals with CVD. According to the findings depicted in
276 **Figure 2**, it was observed that HBV infection exhibited a protective effect on the
277 occurrence of CHD (OR = 0.27, 95% CI: 0.12 – 0.60; $P = 0.001$) and AP (OR = 0.56,
278 95% CI: 0.36 – 0.86; $P = 0.008$). Conversely, HBV infection was identified as a risk

279 factor for AMI (OR = 2.24, 95% CI: 1.40 – 3.57; $P = 0.001$). Furthermore, it was
280 determined that HBV infection did not significantly impact the remaining 11 clinical
281 outcomes in individuals with CAD.

282 **The impact of HBV infection, stratified by DM, on multiple clinical outcomes**

283 **among CVD patients.** Given that the prevalence of DM among patients with and

284 without HBV infection was 48.7% and 62.7%, respectively ($P = 0.002$; **Table 1**), it is

285 evident that the baseline characteristics were not equivalent. Consequently, the

286 presence of DM may exert an influence on cardiovascular outcomes. In this study,

287 DM was employed as a stratified variable to examine the potential impact of HBV

288 infection on clinical outcomes in patients with CVD. The results of our study indicate

289 that the coexistence of DM and HBV infection may significantly increase the risk of

290 AMI (OR = 5.37, 95% CI: 2.91 - 9.92; $P < 0.001$) as well as unfavorable secondary

291 clinical outcomes (OR = 4.34, 95% CI: 2.06 - 9.15; $P < 0.001$) (**Figure 3**). These

292 findings suggest the importance of implementing strict blood sugar control and

293 anti-HBV therapy in patients with this comorbidity.

294 **The impact of DM and HbA1c ($\geq 6\%$ or $< 6\%$) on multiple clinical outcomes**

295 **among CVD patients.** Based on the baseline characteristics of the population

296 statistics, a comprehensive analysis was conducted on a total of 496 individuals,

297 comprising 273 subjects with DM and 223 subjects without DM. The findings

298 revealed that, in comparison to the non-DM group, the DM group exhibited a notably

299 higher prevalence of hypertension history and the administration of atorvastatin 20

300 mg dosage (both $P < 0.05$). Conversely, the prevalence of smoking history,

301 rosuvastatin 10 mg dosage, and overall statin usage were significantly lower in the
302 DM group (all $P < 0.05$). Furthermore, in comparison to the non-DM group, the DM
303 group exhibited elevated levels of MO, NE, MHR, NHR, BNP, ALS, and HbA1c (all
304 $P < 0.05$). Conversely, the DM group displayed a relatively diminished ApoE level
305 when contrasted with the non-DM group. There were no statistically significant
306 differences observed in various demographic and clinical factors, including age,
307 gender, height, weight, BMI, alcohol consumption history, LDL-C level, TG level,
308 HDL-C level, triglyceride-to-HDL-C ratio, ApoA level, ApoB level, Lp(a) level, TC
309 level, non-HDL-C level, CYS-C level, LY count, PLT count, NLR, PLR, AST/ALT,
310 AST level, TBil level, and ALP level, between the two groups (**Supplementary table**
311 **3 and 4**). As shown in **Figure 4**, DM poses a significant risk for CHD (RO = 6.9, 95%
312 CI: 3.2-14.9; $P < 0.001$) among patients with CVD, MI (RO = 2.2, 95% CI: 1.5-3.2; P
313 < 0.001), AP patients who were not prescribed statins prior to admission (RO = 3.5,
314 95% CI: 1.3-9.3; $P = 0.01$), and individuals with hypertension extreme risk (RO = 2.9,
315 95% CI: 2.0-4.2; $P < 0.001$). Among patients who were not prescribed statins prior to
316 admission, those with HbA1c levels ≥ 6 exhibited the highest susceptibility to CHD,
317 as indicated by an OR of 34.4 (95% CI: 4.2 to 283.6). However, it is important to note
318 that the OR results displayed significant variability due to the limited sample size of
319 the CHD group, which consisted of only 14 cases (**Figure 5**). In addition, HbA1c
320 levels ≥ 6 also be recognized as a significant risk factor of AP patients who were not
321 prescribed statins prior to admission (RO = 1.6, 95% CI: 1.1-2.3; $P = 0.019$) and
322 individuals with hypertension extreme risk (RO = 2.7, 95% CI: 1.9-4.1; $P < 0.001$;

323 **Figure 5).**

324 **Comparison of the effects of atorvastatin and rosuvastatin on multiple clinical**
325 **outcomes in patients with CVD.** The **Supplementary table 5** presents a comparison
326 of the effects of atorvastatin and rosuvastatin on 13 clinical outcomes in patients
327 diagnosed with CVD. In comparison to patients prescribed atorvastatin, those
328 prescribed rosuvastatin exhibited the higher susceptibility to CHD and CCU, with OR
329 values of 2.1 (95% CI: 1.0 to 4.2; $P = 0.047$) and 4.1 (95% CI: 2.5 to 6.6; $P < 0.001$),
330 respectively. Additionally, the proportion of patients with NYHA classification and a
331 lower risk of UAP were 0.51 (95% CI: 0.32 to 0.79; $P = 0.003$) and 0.62 (95% CI:
332 0.39 to 0.99; $P = 0.043$), respectively. In comparison to atorvastatin, the
333 administration of rosuvastatin resulted in a statistically significant decrease in the
334 median duration of hospitalization by one day, with a 95% CI ranging from 0.0 to 1.0
335 day ($P = 0.001$; **Supplementary table 6**).

336 **Interaction of statin use with hepatic FIB-4, complete blood count-derived**
337 **inflammation indexes (CBCIIs) or ALBI grade.** The baseline characteristics and
338 statistical comparisons of both quantitative (**Supplementary table 7**) and qualitative
339 (**Supplementary table 8**) parameters of individuals with CVD were using or not
340 using statins. Significant differences were observed in height, weight, platelet count,
341 ALT levels, and AST levels among the three groups (all $P < 0.05$). The use of statins
342 led to a significant decrease in levels of TG, LDL-C, ApoB, and non-HDL-C (all $P =$
343 0.000) (**Supplementary table 7**). Analysis of the data in **Supplementary table 8**
344 reveals statistically significant differences in gender, diabetes, and smoking history

345 among the three groups (all $P < 0.05$). In order to assess the potential impact of statin
346 use on improving clinical outcomes related to CVD by inhibiting the progression of
347 liver fibrosis, we conducted a study to examine the association of different statin
348 drugs and doses with FIB-4 levels in patients with CVD. The findings of our study
349 demonstrated that atorvastatin was associated with lower FIB-4 levels in comparison
350 to non-statin users, whereas rosuvastatin did not exhibit a significant difference in
351 FIB-4 levels compared to non-statin users (**Supplementary table 9**). Our study also
352 revealed that the use of statins was associated with a reduction in the levels of SIRI
353 and SIRI/HDL-C, while also leading to an increase in PMR and SII in patients with
354 CVD (**Supplementary table 9**). The findings of dose-stratification analysis in CVD
355 patients revealed a correlation between the increased dosage of atorvastatin and
356 rosuvastatin and the reduction in FIB-4 levels, suggesting the presence of a
357 dose-response relationship (**Supplementary table 10**). Concurrently, a FIB-4
358 stratification analysis was conducted, revealing that patients treated with atorvastatin
359 exhibited a higher proportion of $\text{FIB-4} < 1.45$ and a lower proportion of $\text{FIB-4} > 3.25$.
360 Nevertheless, the reduction in FIB-4 level with rosuvastatin was not as pronounced as
361 with atorvastatin (**Supplementary table 11**).

362 The ALBI grade is a liver function assessment tool that utilizes measurements of
363 albumin and bilirubin levels. The study examined the impact of statin medications on
364 liver function markers and ALBI grade. Statin use was found to significantly decrease
365 DBIL levels compared to non-statin users, while showing no significant effect on
366 other liver function indices, including ALBI grade (**Supplementary table 12**).

367 Stratified analysis based on ALBI grade revealed that none of the patients progressed
368 to an ALBI grade ≥ -1.39 , indicative of the group with the poorest prognosis.
369 Furthermore, statin drug use did not influence ALBI grade in the remaining two
370 groups (**Supplementary table 13**).

371 **Effect of statin use on atherogenic indices.** As shown in **Supplementary table 14**,
372 In comparison to statin-free group, the group with statin use exhibited a significant
373 decrease in levels of AI, CRI-I, CRI-II, and LCI, whereas adjusted AIP, AIP, and
374 RLP-C did not show a statistically significant difference.

375

376 **DISCUSSION**

377 In our study, the baseline data analysis revealed that individuals with both HBV and
378 CVD exhibited notably reduced levels of TG and Lp(a) compared to those with CVD
379 alone. This observation could potentially be attributed to the varying prevalence of
380 diabetes and the utilization of statins among the patient population. Consequently, it is
381 imperative to stratify the HBV cohort based on their statin and diabetes risk profiles in
382 order to comprehensively assess the diverse clinical outcomes in patients with CVD.
383 The utilization of statins has the capacity to diminish the prevalence of CHD and AP
384 among individuals with CVD associated with HBV infection. Stratification analysis,
385 considering the presence of DM, revealed a notably heightened susceptibility to MI,
386 AMI, and HF in patients with HBV infection combined with CVD. These findings
387 imply that CVD patients with HBV infection should judiciously employ statins and
388 effectively manage blood glucose levels.

389 HBV infection has the potential to give rise to a range of intrahepatic and extrahepatic

390 ailments, encompassing acute and chronic hepatitis, cirrhosis, hepatocellular
391 carcinoma, metabolic syndrome, CVD, and renal injury³⁹⁻⁴¹. The pathogenesis of
392 HBV infection is intricate and multifaceted, essentially manifesting as a multisystem
393 disorder. The underestimation of the influence of HBV infection on atherosclerosis
394 has been observed in academic research. Multiple studies have demonstrated that the
395 inflammation triggered by HBV infection serves as a significant contributing factor to
396 the development of atherosclerosis. Conversely, atherosclerosis also exerts subsequent
397 effects on the severity of chronic HBV infection, thereby establishing a detrimental
398 cycle¹⁷. In patients concomitant HBV and MAFLD decreases the risk of ASCVD
399 when compared with MAFLD alone, which may attribute to antiviral treatment⁴¹.
400 The findings of present studies^{17,41} and our research indicate that the implementation
401 of either antiviral therapy or lipid-lowering statin therapy holds the potential to
402 improve liver metabolism or liver injury, consequently reducing the susceptibility to
403 CVD associated with HBV infection.

404 Our study revealed that HBV infection posed a significant risk for AMI in patients
405 with CVD (OR = 2.24, 95% CI: 1.40-3.57; $P = 0.001$). However, our findings did not
406 indicate a significant association between HBV infection and MI (OR = 1.08, 95%CI:
407 0.69-1.68; $P = 0.815$). Analysis of baseline data demonstrated that the proportion of
408 AMI in patients with both HBV infection and CVD was 39.1% (106/271), which was
409 significantly higher than the proportion in patients with CVD alone (23.1%) (52/225;
410 $P < 0.001$). Currently, there is a lack of pertinent research indicating that HBV
411 infection serves as a risk factor for AMI. Furthermore, the underlying physiological

412 and pathological mechanisms by which HBV infection may contribute to an increased
413 risk of AMI in patients with CVD remain unclear. It is plausible that our findings may
414 be attributed to potential data bias, as we did not conduct a multivariate regression
415 analysis. Moreover, a comprehensive epidemiological investigation with larger
416 sample sizes is necessary to ascertain the risk of HBV infection in relation to AMI.

417 According to a comprehensive survey of over 90,000 individuals, patients with HBV
418 and DM was found to be associated with significantly reduced risks of MI (aHR =
419 0.49; 95% CI: 0.42 to 0.56), ischaemic stroke (aHR = 0.61; 95% CI: 0.56 to 0.67), HF
420 (aHR = 0.50; 95% CI: 0.43 to 0.59), and all-cause mortality (aHR = 0.72; 95% CI:
421 0.70 to 0.75) when compared to DM alone ¹⁴, while the researchers did not provide a
422 specific explanation. Hence, the association between enhanced liver metabolism
423 through antiviral therapy in patients with HBV and its potential correlation with
424 MACE, HF, and all-cause mortality remains uncertain. In our study, the findings of
425 risk stratification based on DM indicate that HBV infection is associated with a
426 decreased risk of CDH in patients with CVD (OR = 0.32, 95% CI: 0.15-0.68; $P =$
427 0.004). However, when HBV infection is combined with DM, it is associated with an
428 increased risk of MI (OR = 2.12, 95% CI: 1.30 – 3.45; $P = 0.002$), AMI (OR = 5.37,
429 95% CI: 2.91 – 9.92; $P < 0.001$), and HF (OR = 2.58, 95% CI: 1.32 - 5.04; $P = 0.005$).

430 These findings indicate that the clinical consequences linked to HBV infection in
431 individuals with DM may have both positive and negative implications, contingent
432 upon various confounding variables including the patient's baseline characteristics,
433 antiviral therapy, diabetes management, and statin administration.

434 Furthermore, a comprehensive analysis was conducted on a cohort of 496 patients
435 diagnosed with CVD to examine the variations in clinical and biochemical markers
436 between individuals with CVD and DM and those without DM. Additionally, the
437 impact of HbA1c levels and DM on various clinical outcomes in patients with CVD
438 was investigated. Moreover, the effects of atorvastatin and rosuvastatin on multiple
439 clinical outcomes in individuals with CVD were also examined. The correlation
440 between DM and the extent of CVD has been examined in prior populations ⁴². The
441 investigation revealed that DM is linked to a greater occurrence of cardiogenic shock,
442 more severe stenosis ($\geq 70\%$) segments, and a higher frequency of complications ⁴³. A
443 recent study encompassed a sample of 23,643 individuals who underwent consecutive
444 coronary CT angiography. In comparison to non-DM patients, those with diabetes
445 exhibited a heightened prevalence of obstructive CAD, characterized by more
446 pronounced stenosis in both the proximal and middle segments of the coronary
447 arteries ⁴⁴. HbA1c serves as a precise diagnostic marker for diabetes, enabling the
448 assessment of average blood sugar levels over a span of 2-3 months, while remaining
449 minimally influenced by acute illnesses. Moreover, it holds the potential to inform
450 treatment decisions. Subjects with HbA1c levels ranging from 5.7% to 6.4% exhibited
451 elevated levels of coronary artery calcium and carotid intima-media thickness
452 compared to subjects with HbA1c levels below 5.7%, suggesting that an increase in
453 HbA1c levels is linked to an augmented burden of coronary and peripheral
454 atherosclerosis in non-diabetic individuals with normal fasting glucose ⁴⁵. A
455 significant correlation was observed between the decrease in HbA1c levels and the

456 reduction in HR for MACE⁴⁶. The meta-regression analysis further demonstrated that
457 the mitigation of cardiovascular events among adult individuals with DM can be
458 partially attributed to a decrease in HbA1c levels⁴⁷. Patients diagnosed with T2DM
459 who exhibit inadequate control of their HbA1c levels (ranging from 8% to 8.9% and
460 equal to or greater than 9%) are found to have comparable or elevated mortality risks
461 when compared to patients diagnosed with CVD⁴⁸. Consequently, it is imperative to
462 prioritize achieving optimal HbA1c levels in order to effectively mitigate risks,
463 prevent mortality, and manage complications associated with DM.

464 The results of our study indicate that elevated HbA1c levels and the presence of DM
465 have a significant influence on various clinical outcomes among individuals
466 diagnosed with CVD. Specifically, our findings demonstrate that individuals with DM
467 and HbA1c levels $\geq 6\%$ are at an increased risk for developing CHD, experiencing MI,
468 AP, and hypertension. Furthermore, our study examined the impact of both
469 atorvastatin and rosuvastatin on various clinical outcomes among individuals
470 diagnosed with CVD. Notably, patients administered rosuvastatin exhibited the
471 greatest susceptibility to CHD and admission to the CCU, accompanied by elevated
472 rates of NYHA classification. Conversely, these individuals experienced a diminished
473 likelihood of developing UAP.

474 The findings of our study suggest an association between statin use and a decreased
475 risk of HBV infection, potentially due to the inhibitory effects of statins on
476 HBV-DNA replication or clearance. It may be prudent to consider reducing or
477 discontinuing statin therapy in patients with HBV infection who exhibit transaminase

478 levels exceeding three times the upper limit of normal. Hence, it is important to
479 acknowledge the potential for bias in this conclusion. Additionally, the administration
480 of anti-HBV therapy to patients with HBV infection could potentially impact the
481 outcome. The quantification of HBV infection in this study was based on HBsAg
482 levels, and while statin use may reduce HBV-DNA levels until they become
483 undetectable, it is unlikely to result in clearance of HBsAg. Multiple studies have
484 documented the potential of statins to decrease the likelihood of advancing to
485 cirrhosis and hepatocellular carcinoma in individuals with HBV infection⁴⁹⁻⁵⁴. This is
486 attributed to the inhibition or eradication of HBV, which is believed to impede the
487 progression to cirrhosis and liver cancer. Klundert et al.⁵⁴ discovered that statins
488 inhibit the replication of the hepatitis B virus and decrease the viability of hepatoma
489 cells by disrupting Rho-GTPases. Our findings align with this consensus. Furthermore,
490 the HBV viral load remains relatively constant in the absence of effective anti-HBV
491 treatment, suggesting that factors other than statins have minimal impact. Therefore, it
492 is plausible to infer that the proposition of statins inhibiting or eradicating HBV is
493 likely valid.

494 To delve deeper into the potential mechanisms of statin therapy in CVD patients to
495 improve clinical outcomes, we conducted additional research on the impact of statin
496 therapy on hepatic function, atherosclerotic burden, and systemic inflammation. The
497 importance of FIB-4 and ALBI grade as the non-invasive indicators for liver fibrosis
498 in predicting CVD among patients with liver diseases or DM has been well
499 documented⁵⁵⁻⁵⁹. Schonmann et al.⁵⁸ found that individuals with advanced fibrosis

500 (FIB-4 \geq 2.67) had a significantly higher risk of cardiovascular disease (HR = 1.60,
501 95% CI: 1.27-2.01) compared to those with inconclusive fibrosis (HR = 1.15, 95% CI:
502 1.01-1.31). Chun et al.⁵⁹ found a significant difference in the cumulative incidence of
503 CVD among groups stratified by FIB-4. The severity of liver fibrosis was found to
504 independently predict the occurrence of CVD in patients with T2DM. Additionally,
505 the study revealed that the utilization of statins may serve as a protective factor (HR =
506 0.603) among individuals with T2DM, thereby mitigating the likelihood of
507 developing CVD⁵⁹. FIB-4 may have utility in the identification of individuals at
508 elevated risk of CVD within the population of patients diagnosed with NAFLD.
509 Conversely, the use of APRI for this purpose is not advised⁶⁰. Our findings indicate
510 that FIB-4 may be more effective than ALBI in assessing liver function in patients
511 undergoing atorvastatin therapy. This is primarily due to the ability of FIB-4 to
512 accurately monitor patients with severe liver damage, which was notably reduced in
513 those receiving atorvastatin treatment. Prior research has indicated that statins may
514 impact the levels of AST and ALT in NAFLD patients, as well as suggested that FIB-4
515 as a non-invasive test has an ability to predict hepatic fibrosis⁶¹.
516 More importantly, our study revealed that both Atorvastatin and Rosuvastatin
517 exhibited a dose-dependent reduction in FIB-4 levels among patients with CVD. A
518 notable increase in the number of patients with FIB-4 grade $<$ 1.45 and a decrease in
519 those with FIB-4 grade $>$ 3.25 were observed, particularly atorvastatin administration.
520 Simon and colleagues⁶² found that the use of statins was linked to a decrease in
521 incident cirrhosis in a dose-dependent manner. Mohanty et al.⁶³ discovered that statin

522 use in patients with HCV is correlated with a reduction of over 40% in the risk of
523 cirrhosis. The prevalence of cirrhosis was found to be 8% lower in the group
524 receiving statin treatment compared to the statins-free group⁶⁴. Furthermore, the use
525 of statins was correlated with a reduced advancement of liver fibrosis and occurrence
526 of hepatocellular carcinoma in a substantial population of Veterans with HCV
527 infection⁶⁴. The collective findings of these studies⁶²⁻⁶⁴ and our own research
528 indicate that statins exhibit the most pronounced antifibrotic effects.

529 CBCII is an important predictor of chronic non-infectious inflammatory response,
530 which is associated with the development of various metabolic system disorders such
531 as fibrosis, hypertension, hyperlipidemia, and hyperglycemia⁶⁵⁻⁶⁷. SIRI and SII are
532 the two important inflammation indicators based on peripheral blood cell count^{32, 68}.
533 Prospective investigations have identified a correlation between elevated levels of
534 white blood cells and their subtypes, such as neutrophils, monocytes, and
535 lymphocytes, with an augmented susceptibility to coronary heart disease and stroke.
536 Neutrophils are capable of releasing a plethora of inflammatory mediators,
537 chemokines, and oxygen free radicals, thereby instigating endothelial cell damage,
538 consequent tissue ischemia, and a pivotal role in the inflammatory response of
539 atherosclerosis^{32,68,69}. The activation and differentiation of monocytes into lipid-laden
540 macrophages is a critical step in the pathogenesis of atherosclerotic plaques^{32,68,69}.
541 Consequently, novel systemic inflammatory markers, such as the SII and SIRI, which
542 are derived from neutrophil counts and other parameters, are likely to be correlated
543 with unfavorable cardiovascular outcomes. In our study, contrasting outcomes were

544 observed between SIRI and SII in assessing the impact of statin use in CVD patients.
545 Specifically, our findings demonstrated a decrease in SIRI levels and an increase in
546 SII levels in patients with CVD following statin therapy. Li et al.⁷⁰ demonstrated that
547 SIRI is a strong predictor of all-cause mortality in CAD patients with low residual
548 inflammatory risk. Numerous studies have indicated that the SII may serve as a
549 potential biomarker for the development of CVD, with elevated levels of SII being
550 linked to an increased risk of CVD⁷¹⁻⁷³. SII and SIRI have been linked to
551 cardiovascular disease, yet the impact of statin therapy on these indices remains
552 inconclusive. Following statin therapy, SII levels exhibited a significant increase,
553 whereas SIRI levels showed a significant decrease. Consequently, the influence of
554 statin therapy on the systemic inflammatory response in CVD patients remains
555 uncertain and warrants further validation in a larger cohort.

556 Utilizing initial data, our study determined that the utilization of statins resulted in a
557 significant decrease in TC and LDL-C levels. Additionally, we conducted a thorough
558 examination of the impact of statin use on atherogenic indices among individuals
559 diagnosed with CVD. Higher values of novel atherogenic indices, including AIP,
560 CRI-I, CRI-II, and LCI, were found to be significantly associated with an increased
561 risk of coronary artery disease (CAD) when compared to lower values³⁵. Many
562 investigations indicate that the AIP serves as a novel marker in the contemporary
563 landscape of CVD, with elevated AIP emerging as an independent prognostic factor in
564 patients with CAD⁷⁴⁻⁷⁷. AI was independently associated with all-cause and CVD
565 mortality among patients undergoing peritoneal dialysis³⁷. Following adjustments for

566 potential confounders, the highest of AI value exhibited a notably increased hazard
567 ratio for both all-cause mortality and CVD mortality when compared to the lowest AI
568 value³⁷. Hence, the majority of atherogenicity indicators hold significant implications
569 for the diagnosis and prognosis of CVD risk events. Currently, there is a lack of
570 relevant literature examining the relationship between statin use and atherogenicity
571 indicators. Our research indicates that the use of statins has a significant impact on
572 reducing levels of AI, CRI-I, CRI-II, and LCI. These findings suggest that statins may
573 have a positive effect on liver fibrosis by improving lipid metabolism. Additionally,
574 atherogenic indices such as AI, CRI-I, CRI-II, and LCI could serve as valuable
575 markers for assessing liver fibrosis in patients undergoing statin therapy for CVD.

576 It is important to acknowledge that our study has several limitations. Firstly, the
577 recruitment of patients was limited to a single center, and the sample size was
578 moderate. Secondly, there is a dearth of information pertaining to the duration of
579 hyperlipidemia, hypertension, and diabetes. Consequently, when assessing the impact
580 of diabetes and its complications, it is not possible to disregard the potential influence
581 of unmeasured confounding factors. Thirdly, the measurement of HbA1c may be
582 susceptible to interference from hemoglobin variants, hereditary hemoglobinopathies,
583 thalassemia, and iron-deficiency anemia. However, HbA1c serves as a reliable
584 indicator of prolonged blood glucose regulation and exhibits reduced inter-individual
585 variability in contrast to impaired glucose tolerance and fasting plasma glucose.

586 Moreover, it is crucial to acknowledge that our analysis solely encompasses a single
587 measurement of HbA1c, thereby rendering the alterations in glycemic control

588 parameters indeterminate. Furthermore, this investigation solely encompasses
589 inpatient data, precluding the assessment of long-term follow-up. Consequently, it is
590 advisable to employ more sophisticated methodologies, such as cohort studies, to
591 further investigate this matter.

592 **CONCLUSION**

593 Our study indicates that CVD patients who also have HBV infection may experience
594 a reduction in MACEs when treated with statins. DM with an HBA1c level of ≥ 6 is
595 identified as risk factor for the development of CHD, MI, AP, and hypertension. The
596 implementation of statins has demonstrated the potential to reduce the incidence of
597 CHD and AP in individuals with CVD. The analysis of stratification, taking into
598 account the presence of DM, has demonstrated a significantly increased vulnerability
599 to MI, AMI, and HF among individuals with HBV infection combined with CVD.
600 Furthermore, our findings reveal that long-term glycemic control should be prioritized
601 in this patient population. Our findings also indicate that FIB-4 could serve as a
602 potential indicator for assessing liver function in individuals undergoing treatment
603 with statins. Statin therapy resulted in reduction in TC and LDL-C levels, as well as
604 improvement of atherogenicity markers such as AI, CRI-I, CRI-II, and LCI. The
605 results of our study indicate that statins may potentially ameliorate liver fibrosis
606 through enhancement of lipid metabolism. Furthermore, atherogenic indices including
607 AI, CRI-I, CRI-II, and LCI may serve as useful indicators for evaluating liver fibrosis
608 in individuals receiving statin treatment for CVD. The observed improvements in
609 hepatic function, atherosclerotic burden, and systemic inflammation associated with

610 statin therapy may contribute to the favorable outcomes among individuals with CVD.

611

612 **Sources of Funding**

613 This work received financial support from the Natural Science Foundation of Shaanxi

614 Province, China (Grant No. 2022SF-243).

615 **Disclosures**

616 Prof. Wang received grants from the Natural Science Foundation of Shaanxi Province,

617 China. The authors declare that they have no competing interests.

618 **Supporting information**

619 **Table S1-Table S14.**

620 **REFERENCES**

- 621 1. Global, regional, and national age-sex-specific mortality for 282 causes of
622 death in 195 countries and territories, 1980-2017: A systematic analysis for the
623 global burden of disease study 2017. *Lancet (London, England)*.
624 2018;392:1736-1788. doi: [10.1016/S0140-6736 \(18\) 32203-7](https://doi.org/10.1016/S0140-6736(18)32203-7).
- 625 2. Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary
626 atherosclerosis and clinical implications for chronic ischemic heart disease
627 management-the plaque hypothesis: A narrative review. *JAMA cardiology*.
628 2023;8:192-201. doi: [10.1001/jamacardio.2022.3926](https://doi.org/10.1001/jamacardio.2022.3926).
- 629 3. Kamstrup PR. Lipoprotein(a) and cardiovascular disease. *Clinical chemistry*.
630 2021;67:154-166. doi: [10.1093/clinchem/hvaa247](https://doi.org/10.1093/clinchem/hvaa247).
- 631 4. Ference BA, Graham I, Tokgozoglul L, Catapano AL. Impact of lipids on
632 cardiovascular health: Jacc health promotion series. *Journal of the American*
633 *College of Cardiology*. 2018;72:1141-1156. doi: [10.1016/j.jacc.2018.06.046](https://doi.org/10.1016/j.jacc.2018.06.046).
- 634 5. Vujkovic M, Keaton JM, Lynch JA, Assimes TL, Chang KM, Cho K, Lee JS,
635 Gaziano JM, Phillips LS, Damrauer SM, DuVall SL, Gao L, Kaestner KH,
636 Susztak K. Discovery of 318 new risk loci for type 2 diabetes and related
637 vascular outcomes among 1.4 million participants in a multi-ancestry
638 meta-analysis. *Nature genetics*. 2020;52:680-691. doi:
639 [10.1038/s41588-020-0637-y](https://doi.org/10.1038/s41588-020-0637-y).
- 640 6. Clarke R, Von Ende A, Hill M, Hopewell JC, Hughes AD, Mayr M, Pechlaner
641 R, Schmidt LE, Theofilatos K, Watkins H, Watkins H, Yin X. Apolipoprotein

- 642 proteomics for residual lipid-related risk in coronary heart disease. *Circulation*
643 *research*. 2023;132:452-464. doi: [10.1161/CIRCRESAHA.122.321690](https://doi.org/10.1161/CIRCRESAHA.122.321690).
- 644 7. Huang Y, Ren Y, Yang H, Ding Y, Liu Y, Yang Y, Mao A, Yang T, Wang Y,
645 Xiao F, He Q, Zhang Y. Using a machine learning-based risk prediction model
646 to analyze the coronary artery calcification score and predict coronary heart
647 disease and risk assessment. *Computers in biology and medicine*.
648 2022;151:106297. doi: [10.1016/j.combiomed.2022.106297](https://doi.org/10.1016/j.combiomed.2022.106297).
- 649 8. Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw
650 LJ, Blankstein R, Miedema MD, Berman DS, Budoff MJ, Krumholz HM,
651 Blaha MJ, Nasir K. Interplay of coronary artery calcium and risk factors for
652 predicting cvd/chd mortality: The cac consortium. *JACC. Cardiovascular*
653 *imaging*. 2020;13:1175-1186. doi: [10.1016/j.jcmg.2019.08.024](https://doi.org/10.1016/j.jcmg.2019.08.024).
- 654 9. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and
655 cardiovascular disease: An update. *Nature reviews. Cardiology*.
656 2010;7:369-375. doi: [10.1038/nrcardio.2010.35](https://doi.org/10.1038/nrcardio.2010.35).
- 657 10. Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and
658 long-term mortality after myocardial infarction in patients with and without
659 diabetes: Changes from 1985 to 2008. *Diabetes care*. 2012;35:2043-2047. doi:
660 [10.2337/dc11-2462](https://doi.org/10.2337/dc11-2462)
- 661 11. Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis b virus (hbv)
662 infection. *Journal of medical virology*. 2015;87:1989-1999. doi:
663 [10.1002/jmv.24270](https://doi.org/10.1002/jmv.24270).

- 664 12. Cacoub P, Asselah T. Hepatitis b virus infection and extra-hepatic
665 manifestations: A systemic disease. *The American journal of gastroenterology*.
666 2022;117:253-263. doi: [10.14309/ajg.0000000000001575](https://doi.org/10.14309/ajg.0000000000001575).
- 667 13. Hamilton EM, Yang L, Avery D. Chronic hepatitis b virus infection and risk of
668 stroke types: A prospective cohort study of 500 000 chinese adults. *Stroke*.
669 2023;54:3046-3053. doi: [10.1161/STROKEAHA.123.043327](https://doi.org/10.1161/STROKEAHA.123.043327).
- 670 14. Kuo CS, Chen YT, Hsu CY, Chang CC, Chou RH, Li SY, Kuo SC, Huang PH,
671 Chen JW, Lin SJ. The impact of chronic hepatitis b infection on major adverse
672 cardiovascular events and all-cause mortality in patients with diabetes: A
673 nationwide population-based study from taiwan. *BMJ open*. 2017;7:e016179.
674 doi: [10.1136/bmjopen-2017-016179](https://doi.org/10.1136/bmjopen-2017-016179).
- 675 15. Ke ZP, Gong M, Zhao G, Geng Y, Cheng K. Association between hbv
676 infection and the prevalence of coronary artery disease in the us population.
677 *Computational and mathematical methods in medicine*. 2022;2022:5062798.
678 doi: [10.1155/2022/5062798](https://doi.org/10.1155/2022/5062798).
- 679 16. Kumar A, Shariff M, Doshi R. Association between past hepatitis b infection
680 and ischemic heart disease: An analysis from the 2007-2016 nhanes data. *The*
681 *American journal of the medical sciences*. 2020;360:372-377. doi:
682 [10.1016/j.amjms.2020.05.034](https://doi.org/10.1016/j.amjms.2020.05.034).
- 683 17. Ranković I, Milivojević V, Pavlović Marković A, Bezmarević M. Interplay
684 between chronic hepatitis b and atherosclerosis: Innovative perspectives and
685 theories. *World journal of gastroenterology*. 2022;28:497-499. doi:

- 686 [10.3748/wjg.v28.i4.497](https://doi.org/10.3748/wjg.v28.i4.497).
- 687 18. Wu VC, Chen TH, Wu M, Cheng CW, Chen SW, Chang CW, Chen CC, Chang
688 SH, Hung KC, Chern MS, Lin FC, Chu PH, Wu CS. Comparison of
689 cardiovascular outcomes and all-cause mortality in patients with chronic
690 hepatitis b and c: A 13-year nationwide population-based study in asia.
691 *Atherosclerosis*. 2018;269:178-184. doi:
692 [10.1016/j.atherosclerosis.2018.01.007](https://doi.org/10.1016/j.atherosclerosis.2018.01.007).
- 693 19. Kim D, Adejumo AC, Yoo ER, Iqbal U, Li AA, Pham EA, Cholankeril G,
694 Glenn JS, Ahmed A. Trends in mortality from extrahepatic complications in
695 patients with chronic liver disease, from 2007 through 2017. *Gastroenterology*.
696 2019;157:1055-1066.e1011. doi: [10.1053/j.gastro.2019.06.026](https://doi.org/10.1053/j.gastro.2019.06.026).
- 697 20. Liu XY, Zhou Y. Influence of hepatitis b virus on the prevalence of diabetes
698 complications in patients with type 2 diabetes. *Journal of diabetes*
699 *investigation*. 2023;14:429-434. doi: [10.1111/jdi.13954](https://doi.org/10.1111/jdi.13954).
- 700 21. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn
701 EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED,
702 Miedema MD, Muñoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J,
703 Ziaieian B. 2019 acc/aha guideline on the primary prevention of cardiovascular
704 disease: A report of the american college of cardiology/american heart
705 association task force on clinical practice guidelines. *Circulation*.
706 2019;140:e596-e646. doi: [10.1161/CIR.0000000000000678](https://doi.org/10.1161/CIR.0000000000000678).
- 707 22. Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng

- 708 F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J. Prevalence of
709 dyslipidemia and availability of lipid-lowering medications among primary
710 health care settings in china. *JAMA network open*. 2021;4:e2127573. doi:
711 [10.1001/jamanetworkopen.2021.27573](https://doi.org/10.1001/jamanetworkopen.2021.27573).
- 712 23. Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and
713 management of cirrhosis, portal hypertension, and hcc. *Hepatology (Baltimore,*
714 *Md.)*. 2023;78:1896-1906. doi: [10.1097/HEP.000000000000278](https://doi.org/10.1097/HEP.000000000000278).
- 715 24. Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee
716 YH. Ezetimibe combination therapy with statin for non-alcoholic fatty liver
717 disease: An open-label randomized controlled trial (essential study). *BMC*
718 *medicine*. 2022;20:93. doi: [10.1186/s12916-022-02288-2](https://doi.org/10.1186/s12916-022-02288-2).
- 719 25. Shaffer LR, Mahmud N. Statins in cirrhosis: Hope or hype? *Journal of clinical*
720 *and experimental hepatology*. 2023;13:1032-1046. doi:
721 [10.1016/j.jceh.2023.05.002](https://doi.org/10.1016/j.jceh.2023.05.002).
- 722 26. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V,
723 Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D,
724 Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L.
725 Statin use and non-alcoholic steatohepatitis in at risk individuals. *Journal of*
726 *hepatology*. 2015;63:705-712. doi: [10.1016/j.jhep.2015.05.006](https://doi.org/10.1016/j.jhep.2015.05.006).
- 727 27. Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin
728 treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease:
729 Is it time to give the emperor a statin robe? *Metabolism: clinical and*

- 730 *experimental*. 2021;121:154796. doi: [10.1016/j.metabol.2021.154796](https://doi.org/10.1016/j.metabol.2021.154796).
- 731 28. Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins' efficacy in
732 non-alcoholic fatty liver disease: A systematic review and meta-analysis.
733 *Clinical nutrition (Edinburgh, Scotland)*. 2022;41:2195-2206. doi:
734 [10.1016/j.clnu.2022.08.001](https://doi.org/10.1016/j.clnu.2022.08.001).
- 735 29. Navarro P, Gutiérrez-Ramírez L, Arias Á, Lucendo AJ, Tejera-Muñoz A.
736 Systematic review and meta-analysis: Prevalence of non-alcoholic fatty liver
737 disease and liver fibrosis in patients with inflammatory bowel disease.
738 *Nutrients*. 2023;15:4507. doi: [10.3390/nu15214507](https://doi.org/10.3390/nu15214507).
- 739 30. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ,
740 Gallego Llera B, López de la Cruz J, Gomollón F. Liver fibrosis in
741 non-alcoholic fatty liver disease and progression to hepatocellular carcinoma
742 in patients with inflammatory bowel disease: A systematic review. *Cancers*.
743 2023;15:3367. doi: [10.3390/cancers15133367](https://doi.org/10.3390/cancers15133367).
- 744 31. Tian YB, Niu H, Xu F, Shang-Guan PW, Song WW. Albi score combined with
745 fib-4 index to predict post-hepatectomy liver failure in patients with
746 hepatocellular carcinoma. *Scientific reports*. 2024;14:8034. doi:
747 [10.1038/s41598-024-58205-5](https://doi.org/10.1038/s41598-024-58205-5).
- 748 32. Li J, He D, Yu J, Chen S, Wu Q, Cheng Z, Wei Q, Xu Y, Zhu Y, Wu S.
749 Dynamic status of sII and sIRI alters the risk of cardiovascular diseases:
750 Evidence from kailuan cohort study. *Journal of inflammation research*.
751 2022;15:5945-5957. doi: [10.2147/JIR.S378309](https://doi.org/10.2147/JIR.S378309).

- 752 33. Xiu J, Lin X, Chen Q, Yu P, Lu J, Yang Y, Chen W, Bao K, Wang J, Zhu J,
753 Zhang X, Pan Y, Tu J, Chen K, Chen L. The aggregate index of systemic
754 inflammation (aisi): A novel predictor for hypertension. *Frontiers in*
755 *cardiovascular medicine*. 2023;10:1163900. doi: [10.3389/fcvm.2023.1163900](https://doi.org/10.3389/fcvm.2023.1163900).
- 756 34. Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: Pathophysiology
757 and the role of calculated lipid indices in assessing cardiovascular risk in
758 patients with hyperlipidemia. *International journal of molecular sciences*.
759 2022;24:75. doi: [10.3390/ijms24010075](https://doi.org/10.3390/ijms24010075).
- 760 35. Mahdavi-Roshan M, Mozafarihashjin M, Shoaibinobarian N, Ghorbani Z,
761 Salari A, Savarrakhsh A, Hekmatdoost A. Evaluating the use of novel
762 atherogenicity indices and insulin resistance surrogate markers in predicting
763 the risk of coronary artery disease: A case-control investigation with
764 comparison to traditional biomarkers. *Lipids in health and disease*.
765 2022;21:126. doi: [10.1186/s12944-022-01732-9](https://doi.org/10.1186/s12944-022-01732-9).
- 766 36. Vargas HO, Nunes SO, Barbosa DS, Vargas MM, Cestari A, Dodd S,
767 Venugopal K, Maes M, Berk M, Castelli risk indexes 1 and 2 are higher in
768 major depression but other characteristics of the metabolic syndrome are not
769 specific to mood disorders. *Life sciences*. 2014;102:65-71. doi:
770 [10.1016/j.lfs.2014.02.033](https://doi.org/10.1016/j.lfs.2014.02.033).
- 771 37. Deng J, Tang X, Tang R, Chen J, Guo H, Zhou Q, Zhan X, Long H, Peng F,
772 Wang X, Wen Y, Feng X, Su N, Tian N, Wu X, Xu Q. Atherogenic index
773 predicts all-cause and cardiovascular mortality in incident peritoneal dialysis

- 774 patients. *Atherosclerosis*. 2023;387:117389. doi:
775 [10.1016/j.atherosclerosis.2023.117389](https://doi.org/10.1016/j.atherosclerosis.2023.117389).
- 776 38. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the
777 cardiovascular system. *Circulation research*. 2017;120:229-243. doi:
778 [10.1161/CIRCRESAHA.116.308537](https://doi.org/10.1161/CIRCRESAHA.116.308537).
- 779 39. Tian T, Song C, Jiang L, Dai J, Lin Y, Xu X, Yu C, Ge Z, Ding Y, Wen Y, Liu
780 B, Shao Y, Shi P, Zhu C, Liu Y, Jing S, Wang Z, Hu Z, Li J. Hepatitis b virus
781 infection and the risk of cancer among the chinese population. *International*
782 *journal of cancer*. 2020;147:3075-3084. doi: [10.1002/ijc.33130](https://doi.org/10.1002/ijc.33130).
- 783 40. Motamed-Gorji N, Egtesad S, Sharafkhah M, Masoudi S, Darvishian M,
784 Eslami L, Gharavi A, Khoshnia M, Roshandel G, Shayanrad A, Hariri S,
785 Merat S, Poustchi H, Malekzadeh R. All-cause and cause-specific mortality in
786 middle-aged individuals with positive hbsag: Findings from a prospective
787 cohort study. *Archives of Iranian medicine*. 2022;25:139-147. doi:
788 [10.34172/aim.2022.24](https://doi.org/10.34172/aim.2022.24).
- 789 41. Cheng YM, Hsieh TH, Wang CC, Kao JH. Impact of hbv infection on clinical
790 outcomes in patients with metabolic dysfunction-associated fatty liver disease.
791 *JHEP reports : innovation in hepatology*. 2023;5:100836. doi:
792 [10.1016/j.jhepr.2023.100836](https://doi.org/10.1016/j.jhepr.2023.100836).
- 793 42. Khawaja T, Linge J, Leinhard OD, Al-Kindi SG, Rajagopalan S, Khera A, de
794 Lemos JA, Joshi P, Neeland IJ. Coronary artery calcium, hepatic steatosis, and
795 atherosclerotic cardiovascular disease risk in patients with type 2 diabetes

796 mellitus: Results from the dallas heart study. *Progress in cardiovascular*
797 *diseases*. 2023;78:67-73. doi: [10.1016/j.pcad.2023.03.002](https://doi.org/10.1016/j.pcad.2023.03.002). Epub 2023 Mar
798 15.

799 43. Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F,
800 Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW,
801 Marco J, Gitt AK. Impact of diabetes mellitus status on coronary
802 pathoanatomy and interventional treatment: Insights from the euro heart
803 survey pci registry. *Catheterization and cardiovascular interventions : official*
804 *journal of the Society for Cardiac Angiography & Interventions*.
805 2011;78:702-709. doi: [10.1002/ccd.22939](https://doi.org/10.1002/ccd.22939).

806 44. Rana JS, Dunning A, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F,
807 Callister TQ, Chang HJ, Cheng VY, Chinnaiyan K, Chow BJ, Cury R, Delago
808 A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann P, Karlsberg RP, Kim
809 YJ, Leipsic J, Labounty TM, Lin FY, Maffei E, Raff G, Villines TC, Shaw LJ,
810 Berman DS, Min JK. Differences in prevalence, extent, severity, and prognosis
811 of coronary artery disease among patients with and without diabetes
812 undergoing coronary computed tomography angiography: Results from 10,110
813 individuals from the confirm (coronary ct angiography evaluation for clinical
814 outcomes): An international multicenter registry. *Diabetes care*.
815 2012;35:1787-1794. doi: [10.2337/dc11-2403](https://doi.org/10.2337/dc11-2403).

816 45. Scicali R, Giral P, Gallo A, Di Pino A, Rabuazzo AM, Purrello F, Cluzel P,
817 Redheuil A, Bruckert E, Rosenbaum D. Hba1c increase is associated with

- 818 higher coronary and peripheral atherosclerotic burden in non diabetic patients.
- 819 *Atherosclerosis*. 2016;255:102-108. doi:
820 [10.1016/j.atherosclerosis.2016.11.003](https://doi.org/10.1016/j.atherosclerosis.2016.11.003).
- 821 46. Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K,
822 Giugliano D. Improvement of glycemic control and reduction of major
823 cardiovascular events in 18 cardiovascular outcome trials: An updated
824 meta-regression. *Cardiovascular diabetology*. 2021;20:210. doi:
825 [10.1186/s12933-021-01401-8](https://doi.org/10.1186/s12933-021-01401-8).
- 826 47. Fralick M, Colacci M, Odutayo A, Siemieniuk R, Glynn RJ. Lowering of
827 hemoglobin a1c and risk of cardiovascular outcomes and all-cause mortality, a
828 meta-regression analysis. *Journal of diabetes and its complications*.
829 2020;34:107704. doi: [10.1016/j.jdiacomp.2020.107704](https://doi.org/10.1016/j.jdiacomp.2020.107704).
- 830 48. Wan EYF, Yu EYT, Mak IL, Youn HM, Chan KS, Chan EWY, Wong ICK,
831 Lam CLK. Diabetes with poor-control hba1c is cardiovascular disease 'risk
832 equivalent' for mortality: Uk biobank and hong kong population-based cohort
833 study. *BMJ open diabetes research & care*. 2023;11. doi:
834 [10.1136/bmjdr-2022-003075](https://doi.org/10.1136/bmjdr-2022-003075).
- 835 49. Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT,
836 Trautwein C, Scorletti E, Seeling KS, Hehl L, Rendel MD, Zandvakili I, Li T,
837 Chen J, Vujkovic M, Alqahtani S, Rader DJ, Schneider KM, Schneider CV.
838 Association of statin use with risk of liver disease, hepatocellular carcinoma,
839 and liver-related mortality. *JAMA network open*. 2023;6:e2320222. doi:

- 840 [10.1001/jamanetworkopen.2023.20222](https://doi.org/10.1001/jamanetworkopen.2023.20222).
- 841 50. Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver
842 cirrhosis in chronic hepatitis b independent of conventional risk factors: A
843 nationwide study. *Hepatology communications*. 2022;6:2455-2464. doi:
844 [10.1002/hep4.2022](https://doi.org/10.1002/hep4.2022).
- 845 51. Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the
846 risk of hepatocellular carcinoma and death in a hospital-based hepatitis
847 b-infected population: A propensity score landmark analysis. *Journal of*
848 *hepatology*. 2015;63:1190-1197. doi: [10.1016/j.jhep.2015.07.009](https://doi.org/10.1016/j.jhep.2015.07.009).
- 849 52. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are asso-
850 -ciated with a reduced risk of hepatocellular cancer: A systematic review
851 and meta-analysis. *Gastroenterology*. 2013;144:323-332. doi: [10.1053/j.gas](https://doi.org/10.1053/j.gastro.2012.10.005)
852 [tro.2012.10.005](https://doi.org/10.1053/j.gastro.2012.10.005).
- 853 53. Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins
854 associate with better clinical outcomes in chronic hepatitis b patients with
855 hbsag seroclearance. *Hepatology international*. 2021;15:881-891. doi:
856 [10.1007/s12072-021-10197-4](https://doi.org/10.1007/s12072-021-10197-4).
- 857 54. van de Klundert M, Ringelhan M, Protzer U. Statins suppress hepatitis b virus
858 replication and reduce hepatoma cell viability by interfering with rho-gtpases.
859 *Journal of hepatology*. 2018;68:S782. doi: [10.1016/S0168-8278\(18\)31833-6](https://doi.org/10.1016/S0168-8278(18)31833-6)
- 860 55. Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between fib-4, all-cause
861 mortality, cardiovascular mortality, and cardiovascular disease risk among

- 862 diabetic individuals: Nhanes 1999-2008. *Frontiers in cardiovascular medicine*.
863 2023;10:1172178. doi: [10.3389/fcvm.2023.1172178](https://doi.org/10.3389/fcvm.2023.1172178).
- 864 56. Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 index predicts
865 long-term all-cause, cardiovascular and liver-related mortality in the adult
866 korean population. *Clinical gastroenterology and hepatology : the official
867 clinical practice journal of the American Gastroenterological Association*.
868 2023;21:3322-3335. doi: [10.1016/j.cgh.2023.04.026](https://doi.org/10.1016/j.cgh.2023.04.026).
- 869 57. Roca-Fernandez A, Banerjee R, Thomaidis-Brears H, Telford A, Sanyal A,
870 Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, Ntusi NA,
871 Cuthbertson DJ, Lai M, Dennis A, Banerjee A. Liver disease is a significant
872 risk factor for cardiovascular outcomes - a uk biobank study. *Journal of
873 hepatology*. 2023;79:1085-1095. doi: [10.1016/j.jhep.2023.05.046](https://doi.org/10.1016/j.jhep.2023.05.046).
- 874 58. Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an
875 independent predictor of cardiovascular morbidity and mortality in the general
876 population. *Digestive and liver disease : official journal of the Italian Society
877 of Gastroenterology and the Italian Association for the Study of the Liver*.
878 2021;53:79-85. doi: [10.1016/j.dld.2020.10.014](https://doi.org/10.1016/j.dld.2020.10.014). Epub 2020 Nov 2.
- 879 59. Chun HS, Lee JS, Kim BK, Lee HW, Lee YH, Kim YD, Kim SU, Park JY,
880 Kim DY, Ahn SH. Association between the severity of liver fibrosis and
881 cardiovascular outcomes in patients with type 2 diabetes. *Journal of
882 gastroenterology and hepatology*. 2021;36:1703-1713. doi:
883 [10.1111/jgh.15387](https://doi.org/10.1111/jgh.15387).

- 884 60. Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring
885 systems for predicting cardiovascular disease risk in patients with
886 nonalcoholic fatty liver disease: A systematic review and meta-analysis.
887 *European journal of gastroenterology & hepatology*. 2022;34:1277-1284. doi:
888 [10.1097/MEG.0000000000002462](https://doi.org/10.1097/MEG.0000000000002462).
- 889 61. Al-Karaghoul M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of
890 statin treatment on non-invasive tests based predictions of fibrosis in a referral
891 pathway for nafld. *BMJ open gastroenterology*. 2022;9:e000798. doi:
892 [10.1136/bmjgast-2021-000798](https://doi.org/10.1136/bmjgast-2021-000798).
- 893 62. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin
894 are associated with dose-dependent reductions in cirrhosis and hepatocellular
895 carcinoma, among patients with hepatitis c virus: Results from erchives.
896 *Hepatology (Baltimore, Md.)*. 2016;64:47-57. doi: [10.1002/hep.28506](https://doi.org/10.1002/hep.28506).
- 897 63. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased
898 risk of decompensation and death in veterans with hepatitis c-related
899 compensated cirrhosis. *Gastroenterology*. 2016;150:430-440.e431.doi:
900 [10.1053/j.gastro.2015.10.007](https://doi.org/10.1053/j.gastro.2015.10.007).
- 901 64. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung
902 RT, Rogal SS. Effect of addition of statins to antiviral therapy in hepatitis c
903 virus-infected persons: Results from erchives. *Hepatology (Baltimore, Md.)*.
904 2015;62:365-374. doi: [10.1002/hep.27835](https://doi.org/10.1002/hep.27835).
- 905 65. Yousaf H, Khan MIU, Ali I, Munir MU, Lee KY. Emerging role of

- 906 macrophages in non-infectious diseases: An update. *Biomedicine &*
907 *pharmacotherapy = Biomedecine & pharmacotherapie*. 2023;161:114426.[doi:](#)
908 [10.1016/j.biopha.2023.114426](https://doi.org/10.1016/j.biopha.2023.114426).
- 909 66. Cho S, Ying F, Sweeney G. Sterile inflammation and the nlrp3 inflammasome
910 in cardiometabolic disease. *Biomedical journal*. 2023;46:100624. [doi:](#)
911 [10.1016/j.bj.2023.100624](https://doi.org/10.1016/j.bj.2023.100624).
- 912 67. Zinellu A, Paliogiannis P. Blood cell count derived inflammation indexes in
913 patients with idiopathic pulmonary fibrosis. *Lung*. 2020;198:821-827. [doi:](#)
914 [10.1007/s00408-020-00386-7](https://doi.org/10.1007/s00408-020-00386-7).
- 915 68. Kong F, Huang J, Xu C, Huang T, Wen G, Cheng W. System inflammation
916 response index: A novel inflammatory indicator to predict all-cause and
917 cardiovascular disease mortality in the obese population. *Diabetology &*
918 *metabolic syndrome*. 2023;15:195. [doi: 10.1186/s13098-023-01178-8](#).
- 919 69. Wang P, Guo X, Zhou Y, Li Z, Yu S, Sun Y, Hua Y. Monocyte-to-high-density
920 lipoprotein ratio and systemic inflammation response index are associated
921 with the risk of metabolic disorders and cardiovascular diseases in general
922 rural population. *Frontiers in endocrinology*. 2022;13:944991. [doi:](#)
923 [10.3389/fendo.2022.944991](https://doi.org/10.3389/fendo.2022.944991).
- 924 70. Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, Wang Z, Feng Y, Wang Q,
925 Guo X, Tang X, Xu J, Song Y, Chen Y, Xu N, Yao Y, Liu R, Zhu P, Han Y,
926 Yuan J. Prognostic significance of inflammation in patients with coronary
927 artery disease at low residual inflammatory risk. *iScience*. 2023;26:108060.

928 [doi: 10.1016/j.isci.2023.108060](https://doi.org/10.1016/j.isci.2023.108060).

929 71. Ye Z, Hu T, Wang J, Xiao R, Liao X, Liu M, Sun Z. Systemic
930 immune-inflammation index as a potential biomarker of cardiovascular
931 diseases: A systematic review and meta-analysis. *Frontiers in cardiovascular*
932 *medicine*. 2022;9:933913. [doi: 10.3389/fcvm.2022.933913](https://doi.org/10.3389/fcvm.2022.933913).

933 72. Ma J, Li K. Systemic immune-inflammation index is associated with coronary
934 heart disease: A cross-sectional study of nhanes 2009-2018. *Frontiers in*
935 *cardiovascular medicine*. 2023;10:1199433. [doi: 10.3389/fcvm.2023.1199433](https://doi.org/10.3389/fcvm.2023.1199433).

936 73. Zhao Z, Zhang X, Sun T, Huang X, Ma M, Yang S, Zhou Y. Prognostic value
937 of systemic immune-inflammation index in cad patients: Systematic review
938 and meta-analyses. *European journal of clinical investigation*.
939 2024;54:e14100. [doi: 10.1111/eci.14100](https://doi.org/10.1111/eci.14100).

940 74. Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, Amani-Beni R. The
941 association of atherogenic index of plasma with cardiovascular outcomes in
942 patients with coronary artery disease: a systematic review and meta-analysis.
943 *Cardiovascular diabetology*. 2024;23:119. [doi: 10.1186/s12933-024-02198-y](https://doi.org/10.1186/s12933-024-02198-y).

944 75. Min Q, Wu Z, Yao J, Wang S, Duan L, Liu S, Zhang M, Luo Y, Ye D, Huang Y,
945 Chen L, Xu K, Zhou J. Association between atherogenic index of plasma
946 control level and incident cardiovascular disease in middle-aged and elderly
947 chinese individuals with abnormal glucose metabolism. *Cardiovascular*
948 *diabetology*. 2024;23:54. [doi: 10.1186/s12933-024-02144-y](https://doi.org/10.1186/s12933-024-02144-y).

949 76. Wang Y, Wang S, Sun S, Li F, Zhao W, Yang H, Wu X. The predictive value of

950 atherogenic index of plasma for cardiovascular outcomes in patients with
951 acute coronary syndrome undergoing percutaneous coronary intervention with
952 ldl-c below 1.8mmol/l. *Cardiovascular diabetology*. 2023;22:150. doi:
953 [10.1186/s12933-023-01888-3](https://doi.org/10.1186/s12933-023-01888-3).

954 77. Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA,
955 Pérez-Maldonado IN. Atherogenic index of plasma: Novel predictive
956 biomarker for cardiovascular illnesses. *Archives of medical research*.
957 2019;50:285-294. doi: [10.1016/j.arcmed.2019.08.009](https://doi.org/10.1016/j.arcmed.2019.08.009).

958

959 **Figure legends**

960 **Figure 1** Flow diagram of cohort selection. Consequently, a final sample size of 496
961 participants was included in the study. The patients were categorized into two groups
962 according to their surface antigen status: patients with coexisting CVD and HBV (n =
963 225) and patients with CVD alone (n = 271). CVD, cardiovascular disease; HBV,
964 hepatitis B virus; HBsAg, hepatitis B surface antigen.


965 **Figure 2** The impact of HBV infection, stratified by statins use, on multiple clinical
966 outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI,
967 myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
968 care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
969 failure.


970 **Figure 3** The impact of HBV infection, stratified by DM, on multiple clinical
971 outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI,

972 myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
973 care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
974 failure.

975 **Figure 4** The impact of DM, stratified by statins use, on multiple clinical outcomes
976 among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI, myocardial
977 infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI,
978 acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure.

979 **Figure 5** The impact of HbA1c ($\geq 6\%$ or $< 6\%$), stratified by statins use, on multiple
980 clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease;
981 MI, myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
982 care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
983 failure.





Characteristics	Total (N)	OR (95% CI)	P value
CDH	496		0.004
no	45	Reference	
yes	451	0.32 (0.15 - 0.68)	
MI (non-DM)	223		0.384
no	164	Reference	
yes	59	0.76 (0.42 - 1.40)	
MI (DM)	273		0.002
no	154	Reference	
yes	119	2.12 (1.30 - 3.45)	
AP	496		0.084
no	137	Reference	
yes	359	0.68 (0.45 - 1.03)	
Hypertension (extreme risk)	496		0.828
no	299	Reference	
yes	197	0.94 (0.65 - 1.37)	
CCU	496		0.497
no	396	Reference	
yes	100	1.20 (0.77 - 1.87)	
AMI (non-DM)	223		0.396
no	138	Reference	
yes	85	0.79 (0.45 - 1.37)	
AMI (DM)	273		< 0.001
no	200	Reference	
yes	73	5.37 (2.91 - 9.92)	
UAP	496		0.412
no	99	Reference	
yes	397	0.81 (0.51 - 1.27)	
HF (non-DM)	223		0.519
no	175	Reference	
yes	48	0.81 (0.42 - 1.55)	
HF (DM)	273		0.005
no	227	Reference	
yes	46	2.58 (1.32 - 5.04)	
NYHA classification	496		0.468
Class I	108	Reference	
≥ Class II	388	0.83 (0.54 - 1.28)	
Killip classification	496		0.243
Class I	485	Reference	
≥ Class II	11	2.25 (0.59 - 8.59)	
Secondary clinical outcome (non-DM)	223		0.981
no	37	Reference	
yes	186	1.01 (0.49 - 2.09)	
Secondary clinical outcome (DM)	273		< 0.001
no	47	Reference	
yes	226	4.34 (2.06 - 9.15)	
Primary clinical outcome	496		0.847
no	65	Reference	
yes	431	0.91 (0.53 - 1.56)	

0.0 2.5 5.0 7.5 10.0

Characteristics	Total (N)	OR (95% CI)	P value
CDH	494		< 0.001
no	44	Reference	
yes	450	6.9 (3.2 - 14.9)	
MI	494		< 0.001
no	316	Reference	
yes	178	2.2 (1.5 - 3.2)	
AP (no statins use)	79		0.01
no	34	Reference	
yes	45	3.5 (1.3 - 9.3)	
AP (atorvastatin 20 mg)	225		0.063
no	51	Reference	
yes	174	1.8 (1.0 - 3.4)	
AP (rosuvastatin 10 mg)	190		0.669
no	51	Reference	
yes	139	0.87 (0.46 - 1.65)	
Hypertension (extreme risk)	494		< 0.001
no	297	Reference	
yes	197	2.9 (2.0 - 4.2)	
CCU	494		0.554
no	394	Reference	
yes	100	1.2 (0.7 - 1.9)	
AMI	494		0.006
no	337	Reference	
yes	157	0.57 (0.39 - 0.84)	
UAP	494		0.059
no	99	Reference	
yes	395	0.63 (0.39 - 0.99)	
HF	494		0.166
no	403	Reference	
yes	93	0.70 (0.45 - 1.11)	
NYHA classification	494		0.879
Class I	108	Reference	
≥ Class II	386	1.1 (0.7 - 1.6)	
Killip classification	494		0.195
Class I	483	Reference	
≥ Class II	11	3.3 (0.7 - 15.7)	
Secondary clinical outcome	494		0.787
no	84	Reference	
yes	410	0.91 (0.57 - 1.46)	
Primary clinical outcome	494		0.208
no	65	Reference	
yes	429	0.68 (0.40 - 1.17)	

Characteristics	Total (N)	OR (95% CI)	P value
CDH (no statins use)	76		< 0.001
no	14	Reference	
yes	62	34.4 (4.2 - 283.6)	
CDH (atorvastatin 20 mg)	218		0.085
no	19	Reference	
yes	199	2.3 (0.9 - 5.9)	
CDH (rosuvastatin 10 mg)	186		1
no	8	Reference	
yes	178	1.2 (0.3 - 5.1)	
MI	480		0.024
no	305	Reference	
yes	175	1.6 (1.1 - 2.3)	
AP (no statins use)	76		0.019
no	33	Reference	
yes	43	3.1 (1.2 - 8.1)	
AP (atorvastatin 20 mg)	218		0.09
no	48	Reference	
yes	170	1.7 (0.9 - 3.3)	
AP (rosuvastatin 10 mg)	186		0.004
no	50	Reference	
yes	136	0.37 (0.18 - 0.74)	
Hypertension (extreme risk)	480		< 0.001
no	288	Reference	
yes	192	2.7 (1.9 - 4.1)	
CCU	480		0.341
no	381	Reference	
yes	99	1.3 (0.8 - 2.1)	
AMI	480		0.903
no	329	Reference	
yes	151	0.96 (0.65 - 1.41)	
UAP	480		0.205
no	95	Reference	
yes	385	0.72 (0.45 - 1.15)	
HF	480		0.48
no	392	Reference	
yes	88	0.82 (0.51 - 1.31)	
NYHA classification	480		0.408
Class I	105	Reference	
≥ Class II	375	0.81 (0.52 - 1.26)	
Killip classification	480		0.066
Class I	469	Reference	
≥ Class II	11	6.9 (0.9 - 53.2)	
Secondary clinical outcome	480		0.222
no	82	Reference	
yes	398	0.71 (0.43 - 1.17)	
Primary clinical outcome	480		0.689
no	62	Reference	
yes	418	0.86 (0.50 - 1.49)	

Table 1. Baseline characteristics of CVD with HBV and CVD alone participants.

Indices	CVD	HBV+CVD	t/χ^2	P-value
N	225	271	0.333	
age (years, mean \pm SD)	60.21 \pm 10.41	59.90 \pm 10.18		0.739
Gender			4.463	0.035
Female [n (%)]	66(29.3%)	104(38.4%)		
Male [n (%)]	159(70.7%)	167(61.6%)		
Hypertension [n (%)]			0.328	0.567
No	75(33.3%)	97(35.8%)		
Yes	150(66.7%)	174(64.2%)		
DM [n (%)]			9.679	0.002
No	84(37.3%)	139(51.3%)		
Yes	141(62.7%)	132(48.7%)		
Smoking history [n (%)]			0.656	0.418
No	145(64.4%)	184(67.9%)		
Yes	80(35.5%)	87(32.1%)		
Drinking history [n (%)]			0.562	0.453
No	188(83.6%)	233(86.0%)		
Yes	37(16.4%)	38(14.0%)		
Height (cm)	167.00 \pm 7.19	165.00 \pm 8.42	1.900	0.058
Weight (kg)	70.42 \pm 10.46	68.25 \pm 12.23	2.038	0.042
BMI (kg/m ²)	25.23 \pm 3.22	24.68 \pm 3.76	1.66	0.098
Inpatient days (day)	3.70 \pm 1.68	4.12 \pm 2.91	-1.910	0.057
Pre-hospital medication [n (%)]			69.551	0.000
No	2(0.9%)	77(28.4%)		
Yes	223(99.1%)	194(71.6%)		
Statin use [n (%)]			11.102	0.011
No	2(0.9%)	16(5.9%)		
rosuvastatin	88(39.1%)	118(43.5%)		
atorvastatin	134(56.9%)	136(50.2%)		
simvastatin	1(0.4%)	1(0.4%)		
Dosage (mg/day)	16.87 \pm 7.43	15.55 \pm 6.59	2.037	0.042
NYHA classification [n (%)]			0.761	0.383
I	45(20%)	63(23.2%)		
II-IV	180(80%)	208(76.8%)		
Kililip classification [n (%)]			1.485	0.223
I	222(98.7%)	263(97.0%)		
II-IV	3(1.3%)	8(3.0%)		
Adverse event				
AMI [n (%)]			14.504	0.000
No	173(76.9%)	165(60.9%)		
Yes	52(23.1%)	106(39.1%)		

UAP [n (%)]			0.431	0.512
No	42(18.7%)	57(21%)		
Yes	183(81.3%)	214(79%)		
HF [n (%)]			3.092	0.079
No	190(84.4%)	212(78.2%)		
Yes	35(15.6%)	59(21.8%)		
LDL-C (mmol/L)	2.01±0.82	2.05±0.90	-0.418	0.676
TG (mmol/L)	1.45±0.83	1.26±0.75	2.678	0.008
HDL-C (mmol/L)	0.97±0.24	0.96±0.24	0.518	0.605
ApoA (g/L)	1.13±0.18	1.10±0.19	1.879	0.061
ApoB (g/L)	0.69±0.23	0.68±0.22	0.453	0.651
ApoE (mmol/L)	33.22±14.79	32.40±13.63	0.641	0.522
Lp(a) (mg/L)	330.17±296.68	262.34±247.03	2.767	0.006
TC (mmol/L)	3.66±1.01	3.54±1.00	1.309	0.191
non-HDL-C (mmol/L)	2.68±0.94	2.58±0.94	1.094	0.275
CYS-C (mg/L)	0.93±0.18	0.98±0.35	-1.906	0.057
LY (× 10 ⁹ /L)	1.51±0.58	1.55±0.58	-0.711	0.478
MO (× 10 ⁹ /L)	0.45±0.20	0.43±0.22	1.205	0.229
NE (× 10 ⁹ /L)	4.72±1.76	4.42±1.95	1.794	0.073
PLT (× 10 ⁹ /L)	208.41 ± 59.35	190.94 ± 61.39	3.195	0.001
NHR	5.19±2.38	4.99±2.76	0.811	0.418
MHR	0.50±0.27	0.49±0.36	0.312	0.755
NLR	3.66±2.35	3.99±2.76	1.165	0.245
PLR	153.20±63.91	139.16±73.53	2.236	0.026
THR	1.63±1.22	1.46±1.20	1.542	0.124
BNP (pg/L)	477.90±928.33	839.05±2948.05	-1.761	0.079
HbA1c (%)	6.49±1.24	6.43±1.35	0.453	0.651
HBsAg (IU/mL)	0.00±0.00	208.15 ± 652.68	-4.787	0.000
HbsAb (mIU/mL)	62.44±137.92	3.99 ± 20.19	6.69	0.000
HBeAg (S/CO)	0.38±0.06	26.58 ± 179.70	-2.153	0.032
HBeAb (S/CO)	2.41±2.86	7.84 ± 1.07	1.008	0.314
HbcAb (S/CO)	2.41±2.86	7.84 ± 1.07	-28.16	0.000
ALT (U/L)	29.91±19.45	31.33 ± 19.74	-0.925	0.355
AST (U/L)	37.69 ± 66.37	41.57 ± 67.14	-0.642	0.521
AST/ALT	1.21 ± 0.96	1.26 ± 1.03	-0.548	0.584
TBil (μmol/L)	14.24 ± 6.83	14.97 ± 6.76	-1.164	0.245
ALP (U/L)	78.85 ± 2.94	84.83 ± 92.29	-0.922	0.357

AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure;
HbA1c, hemoglobin A1c; BNP, brain natriuretic peptide; ALT, glutamic-pyruvic
transaminase; AST, glutamic oxalacetic transaminase; TBil, total bilirubin; ALP,

alkaline phosphatase; HBsAg, hepatitis B surface antigen; HbsAb, hepatitis B surface antibody; HBeAg, hepatitis E surface antigen; HbeAb, hepatitis E surface antibody; HbcAb, hepatitis B core antibody; TG, triglycerides; Lp(a), lipoprotein(a); PLR, platelet-to-lymphocyte ratio, PLT, platelet count; MO, Monocyte count; NE, neutrophil count; CVD, cardiovascular disease; HBV, hepatitis B virus; DM, diabetes mellitus; THR, thyroid hormone receptor; NHR, nuclear hormone receptor; MHR, monocyte-to-high-density lipoprotein-cholesterol ratio; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoA, apolipoprotein A; ApoB, apolipoprotein B; ApoE, apolipoprotein E; TC, total cholesterol; no-HDL-C, non-HDL cholesterol; CYS-C, cystatin C.

Table 2. Relationship between statin use and HBV infection

Statins	HBV infection		Total (%)	χ^2	P-value (two-sided)
	negative	positive			
no use (pre-admission)	2 (2.5%)	77 (97.5%)	79 (100%)	76.835	0.000
atorvastatin	134 (59.6%)	91 (40.4%)	225 (100%)		
rosuvastatin	88 (46.3%)	102 (53.7%)	190 (100%)		
total	224	270	494		
OR (no use/atorvastatin)	0.018 (95% CI: 0.004 to 0.074)			76.904	0.000
OR (no use/rosuvastatin)	0.030 (95% CI: 0.007 to 0.126)			48.048	0.000
OR (atorvastatin/rosuvastatin)	1.940 (95% CI: 1.280 to 2.940)			9.979	0.002

Table 3. Relationship between statin use and quantitative parameters of HBV

Variables	Statins use	N	P50 (P25 – P75)	Mean ± SD	Range
HBsAg	No use=0	79	>250 (26 to >250)		<0.05 to >250
	atorvastatin =1	225	<0.05(<0.05 to 129)		<0.05 to >250
	rosuvastatin=2	190	2(<0.05 to 174)		<0.05 to >250
	measure		H = 65.606		
	P		0.000		
Median Difference(0-1)			70(95% CI: 26 to 125)		
Median Difference(0-2)			63(95% CI: 18 to 117)		
Median Difference(1-2)			0(95% CI: 0 to 0)		
HBsAb	No use=0	73	0.58(0.20 to 1.45)	2.4±7.9	0 to 52
	atorvastatin =1	199	2.10(0.58 to 20.97)	48±133	0 to 951
	rosuvastatin=2	181	1.31(0.43 to 5.98)	21±57	0 to 338
	measure		H = 31.257		
	P		0.000		
HBeAg	No use=0	73	0.34(0.31 to 0.42)	0.68±2.18	0.01 to 19
	atorvastatin =1	214	0.39(0.34 to 0.43)	9±111	0.01 to 1617
	rosuvastatin=2	186	0.39(0.34 to 0.43)	26±175	0.0225 to 1438
	measure		H = 8.044		
	P		0.018		
HBeAb	No use=0	73	0.01(0.01 to 0.02)	0.20±0.48	0.01 to 2
	atorvastatin =1	214	0.86(0.02 to 1.76)	1.17±3.07	0 to 43
	rosuvastatin=2	186	0.47(0.01 to 1.74)	1.75±6.27	0.01 to 51
	measure		H = 47.239		
	P		0.000		
HBcAb	No use=0	73	7.89(7.09 to 8.61)	7.69±1.57	0.06 to 10
	atorvastatin =1	214	6.06(0.16 to 7.62)	4.65±3.46	0.04 to 11
	rosuvastatin=2	186	7.02(0.62 to 8.04)	5.26±3.53	0.03 to 11
	measure		H = 47.295		
	P		0.000		
HBV DNA	No use=0	42	129(<100 to 2103)		<10 to 11800000
	atorvastatin =1	121	<100(<100 to <100)		<10 to 1310000
	rosuvastatin=2	111	<100(<100 to <100)		<10 to 476000000
	measure		H = 5.522		

	P		0.063		
--	---	--	-------	--	--

Table 4. Relationship between statin dose and HbsAg quantification.

Statins use	HbsAg quantification			J-T	P (two-sided)
	N	P50(P25–P75)	Range		
no use (pre-admission)	79	251(26 to >250)	<0.05 to >250		
atorvastatin (10 mg)	19	78(<0.05 to >250)	<0.05 to >250		
atorvastatin (20 mg)	182	<0.05 (<0.05 to 83)	<0.05 to >250		
atorvastatin (40 mg)	19	<0.05 (<0.05 to >250)	<0.05 to >250	-7.615	0.000
rosuvastatin (10 mg)	8	17(<0.05 to 198)	<0.05 to >250		
rosuvastatin (20 mg)	166	1(<0.05 to 112)	<0.05 to >250		
rosuvastatin (40 mg)	12	80(<0.05 to >250)	<0.05 to >250	-5.936	0.000